Covid cases in India: The recovery count stood at 98.32%, the highest since then. (File)
Two doses of Covaxin are 50 per cent effective against symptomatic disease, according to the first real-world assessment of India's indigenous COVID-19 vaccine published in The Lancet Infectious Diseases journal.
Results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns.
The latest study assessed 2,714 hospital workers at the All India Institute of Medical Sciences (AIIMS) in Delhi, from April 15-May 15, who were symptomatic and underwent RT-PCR test for COVID-19 detection.
Researchers noted that the Delta variant was the dominant strain in India during the study period, accounting for approximately 80 per cent of all confirmed COVID-19 cases.
India added 7,579 new coronavirus cases and 236 related fatalities on Tuesday, pushing the cumulative tally to 3,45,26,480 infections and the death count to 4,66,147, according to yesterday's official update. The active cases stood at 1,13,584, comprising 0.33 per cent of the total count, the lowest since March 2020. The recovery count stood at 98.32 per cent, the highest since then.
Here are the LIVE Updates on Coronavirus cases in India:
COVID-19 UPDATE118.44 Crore vaccine doses have been administered so far under Nationwide Vaccination Drive
Recovery Rate currently at 98.33%; Highest since March 2020
10,949 recoveries in the last 24 hours increases Total Recoveries to 3,39,57,698
9,283 new cases in the last 24 hours
India's Active caseload stands at 1,11,481; lowest in 537 days
Active cases account for less than 1% of total cases, currently at 0.32%; Lowest since March 2020
Daily positivity rate (0.80%) less than 2% for last 51 days
Weekly Positivity Rate (0.93%) less than 2% for last 61 days
Britain's Prince Charles To Open New AstraZeneca Research CentreBritain's Prince Charles will formally open a new 1 billion pound ($1.3 billion) AstraZeneca research and development (R&D) facility on Tuesday, as the company aims to fuel the growth of its drug pipeline.
AstraZeneca has supplied two billion doses of its COVID-19 vaccine, developed at Oxford University, and is also looking to bring a preventative antibody cocktail against COVID-19 to market.
But while the company is setting up a separate division for vaccine and antibody therapies in light of the coronavirus pandemic, it has also strengthened other areas of research
Earlier this year, AstraZeneca completed the $39 billion purchase of rare-disease specialist Alexion.
Four Army Officers, Fully Vaccinated, Test Covid Positive In IndoreFour fully-vaccinated Army officers, two of them participating in a course of the Indian Institute of Management (IIM), tested positive for coronavirus in Madhya Pradesh's Indore district, an official said on Tuesday.
"Four Army officers have tested positive for coronavirus in the last three days in Indore. They had received both doses of the anti-COVID-19 vaccine. They have no symptoms and their condition is fine," said Dr Amit Malakar, nodal officer, COVID-19, Indore.
He said two of the infected officers are residents of the Army Cantonment located in nearby Mhow town and two others are enrolled for the IIM Indore's Certificate Course in Business Management for Defence Officers (CCBMDO).
Covaxin 50% Effective When Delta Was Dominant, Shows Lancet StudyTwo doses of Covaxin are 50 per cent effective against symptomatic disease, according to the first real-world assessment of India's indigenous COVID-19 vaccine published in The Lancet Infectious Diseases journal.
Results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns.
In Maharashtra District, This Is Penalty For Not Taking 1st Vaccine ShotIn a bid to ramp up anti-COVID-19 vaccination coverage in Maharashtra's Aurangabad district, authorities have ordered impounding of autorickshaws if their drivers are found to have not taken even a single jab.
Simultaneously, tour and travel operators cannot sell tickets to passengers who are not inoculated, as per the orders issued late Monday night by district collector Sunil Chavan. These orders will come into effect from November 25.
Aurangabad district in the Marathwada region is one of the laggard districts in terms of vaccination coverage. The district collector had virtually attended a meeting chaired by Prime Minister Narendra Modi earlier this month of districts with low vaccination coverage.
Pfizer Vaccine 100% Effective In Adolescents After 4 Months, Says Company
